This pilot clinical trial suggests that this new impregnated
TLC-NOSF matrix (UrgoStart Contact) could
be an interesting adjunct in the therapeutic strategy
of these chronic wounds. It now remains necessary
to consolidate these encouraging preliminary results
with clinical data from a randomised controlled
trial in patients with more complex and severe
neuropathic DFU.